Pluristem Appoints Arnon Nagler, M.D., MSc. to Scientific Advisory Board.HAIFA, Israel -- Pioneer and World-Acclaimed Leader in Field of Umbilical Cord Blood umbilical cord blood Transplantation A source of primitive and stem cells that can be used to reconstitute BM destroyed by aplastic anemia or by RT or chemotherapy for CA, lymphoproliferative malignancies. See Bone marrow transplantation, Stem cell therapy. , Cord Blood Banking and Stem Cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. Separation and Treatment, to Bring Development Activities to Scientific and Major Pharma Communities Pluristem Life Systems, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: PLRS PLRS Position Location Reporting System PLRS Passive Laser Restraint System (Knight Rider/KITT) ) (the "Company"), a biotechnology company dedicated to the expansion of stem cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young from umbilical cord blood to address a myriad of fatal illnesses, today announced that Arnon Nagler, M.D., M.S.c. has joined the Company's Scientific Advisory Board. Professor Nagler is a pioneer and world renowned leader in the field of human umbilical cord blood. His first publication addressing stem cell separation and purification from human umbilical cord blood was published in 1994. He established the first cord blood bank in Israel in 1994 and performed the first related and unrelated cord blood cord blood n. Blood present in the umbilical vessels at the time of delivery. transplants in Israel in 1994 and 1996 respectively. Professor Nagler, additionally, was part of the team that performed the first gene therapy cord blood transplantation in Israel in a child. - Professor Nagler is founding member of NetCord (the European network of cord blood therapy) and a formal cord blood inspection of the FACHT/NetCord organization. Professor Nagler's cord blood bank at Sheba Medical Center The Chaim Sheba Medical Center (Hebrew: המרכז הרפואי ע"ש חיים שיבא - תל was recently accredited accredited recognition by an appropriate authority that the performance of a particular institution has satisfied a prestated set of criteria. accredited herds cattle herds which have achieved a low level of reactors to, e.g. by the NMDP NMDP National Marrow Donor Program NMDP National Missile Defense Program . Among Dr. Nagler's myriad of awards, his most recent include the Best Abstract Award from the American Society of Bone and Marrow Transplantation (ABSMT) in February 2004 and the Best Abstract from the National Marrow Donor Program The National Marrow Donor Program (NMDP) is a nonprofit organization based in Minneapolis, Minnesota, that operates the federally funded registry of volunteer hematopoietic cell donors in the United States. These potential donors, numbering more than 6. Meeting in October, 2004. Professor. Nagler has received over forty grants from government, research associations, foundations and pharmaceutical companies for his ongoing research. He holds over forty patents and trademarks, has been the lead investigator on over fifteen clinical trials, is an international sought-after lecturer, and widely published. His tenure with leading edge biotech and pharmaceutical companies included his role as Technical Leader and Medical Advisor to Gamida Cell. Dr. Nagler is a Professor Medicine at Tel-Aviv University, Director of Hematology at Chaim Sheba Medical Center, Tel-Hashomer and is also Director of Bone Marrow Transplantation Bone Marrow Transplantation Definition The bone marrow—the sponge-like tissue found in the center of certain bones—contains stem cells that are the precursors of white blood cells, red blood cells, and platelets. and the Cord Blood Bank. Dr. Nagler served as a fellow in medicine/hematology at Stanford University School of Medicine Stanford University School of Medicine is affiliated with Stanford University and is located at Stanford University Medical Center in Stanford, California, adjacent to Palo Alto and Menlo Park. from 1986 until 1989 and is a member of the American Society of Hematology. "Pluristem's technology holds great potential in the field of tissue engineering and the expansion of umbilical cord blood stem cells. I hope to assist them in exploring a number of opportunities in the scientific realm and thoroughly analyze the technology and bring it to its full potential," stated Professor Arnon Nagler. "Professor Nagler's acceptance of this appointment is a tremendous honor to Pluristem. His ground-breaking and ongoing work in the field of human umbilical cord blood along with his unbreakable ties to the scientific and pharmaceutical communities are of great value to us as we move our science to the development stages and on to clinical trials," stated Zami Aberman, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "Professor Nagler's appointment represents one of the strongest endorsements of our technology and the abilities of the U.S. patented PluriX(TM) bioreactor bioreactor a container in which living organisms carry out a biological reaction. that exists," Aberman concluded. About Pluristem Pluristem is a biopharmaceutical company developing stem cell products for cell regenerative therapy. Pluristem's platform for expanding stem cells offers breakthrough technology and multiple product opportunities in many therapeutic areas. Pluristem has exclusive rights to the Plurix(TM) cell expansion system under a licensing agreement with Technion Institute of Technology and the Weisman Institute of Science. For more information, visit the Company's website at: www.pluristem.com. Safe Harbor Statement This press release contains statements, which may constitute "forward-looking statements". Those statements include statements regarding the intent, belief or current expectations of Pluristem Life Systems, Inc., and members of our management as well as the assumptions on which such statements are based. Forward-looking statements in this release include statements that include Pluristem's technology holds great potential in the field of tissue engineering and the expansion of umbilical cord blood stem cells; that Professor's Nagler's contacts and experience are of great value to us as we move our science to the development stages and on to clinical trials; and that our platform for expanding stem cells offers breakthrough technology and multiple product opportunities in many therapeutic areas. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products; Professor Nagler's may be unable to make contacts for us or his contacts may not be interested in our company; Professor Nagler may cease being on our advisory board before being able to assist us; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion